Illumina, Inc. (ILMN) Stock Price, Fundamentals & Analysis

What ILMN does

Illumina, Inc. (ILMN) provides sequencing- and array-based solutions for genetic and genomic analysis across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company sells sequencing- and array-based instruments and consumables, including reagents, flow cells, and library preparation kits; whole-genome sequencing kits; and targeted resequencing kits for exomes, specific genes, and RNA or other genomic regions. It also offers whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services to genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics firms. Illumina, Inc. markets and distributes its products directly and through life-science distributors, and it has a collaboration with Labcorp Holdings Inc.

Key numbers explained

• 255.38 USD is the current share price, the amount you would pay for one share in the market.
• +3.2% is today's price change, showing the percentage move relative to the previous close.
• 38.56B USD is the market capitalization, the total value of all outstanding shares; Illumina, Inc. is large enough to be part of the S&P 500.
• The trailing P/E ratio of 46.1 divides the current price by the last 12 months of earnings per share (5.54 USD), showing how much investors pay for each dollar of recent earnings.
• The forward P/E ratio of 41.8 uses expected future earnings, which can be more relevant for growth-oriented companies.
• 0% dividend yield and 0% share of earnings paid out as dividends mean Illumina, Inc. does not currently pay a cash dividend.
• 1.47 beta indicates the stock tends to move about 47% more than the overall market in either direction.
• 162.1% price change over the last 52 weeks highlights the strong rise from the low of 88 to the high of 256.17.
• 9.4% revenue growth and 18.3% profit margin show top-line expansion and healthy profitability.
• 32.3% return on equity measures how effectively the company generates profit from shareholders' equity.

What to watch

Investors typically monitor Illumina, Inc. alongside peers such as Charles River Laboratories (CRL), DaVita (DVA), Solventum (SOLV), Steris (STE), and ResMed (RMD), as well as broader healthcare names like CVS Health (CVS) and Mettler Toledo (MTD). Key factors include regulatory developments for genetic tests and instruments, reimbursement policies from insurers and government programs, competitive dynamics in the genomics space, and the company's ability to convert revenue growth into sustained earnings. The next earnings report is scheduled for 29 oct. 2026, which will provide updated figures on sales, margins, and guidance.